Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2015-01-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
NCT03964480
Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
NCT05934864
Minimal Residual Disease in Peripheral T-cell Lymphoma
NCT03297697
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
NCT06089941
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
NCT01142674
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Subtypes are as followings:
Anaplastic large cell lymphoma angioimmunoblastic T cell lymphoma Peripheral T cell lymphoma-NOS Enteropathy-associated T cell lymphoma Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Primary cutaneous gamma-delta T-cell lymphoma Primary cutaneous CD8+ aggressive epidermotropic lymphoma
2. Scheduled to receive chemotherapy of curative intent
3. 19 years old or over
4. Expected survival is more than 6 months
5. Informed consent
Exclusion Criteria
* Extranodal NK/T cell lymphoma
* Other than peripheral T cell lymphoma
2. Other combined malignancy
3. Previous history of chemotherapy or radiation therapy
4. No informed consent
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Asan Medical Center
OTHER
Keimyung University Dongsan Medical Center
OTHER
Kosin University Gospel Hospital
OTHER
Dankook University
OTHER
Soonchunhyang University Hospital
OTHER
Ajou University School of Medicine
OTHER
Yeungnam University Hospital
OTHER
Ulsan University Hospital
OTHER
Inje University
OTHER
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
OTHER
Hallym University Medical Center
OTHER
Hanyang University Seoul Hospital
OTHER
Seoul National University Hospital
OTHER
Pusan National University Hospital
OTHER
National Health Insurance Service Ilsan Hospital
OTHER
Hanyang University
OTHER
Korea Cancer Center Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sujin Kang
CRA
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Won Seog Kim, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dankook University Hospital
Cheonan, , South Korea
Keimyung University Dongsan Hospital
Daegu, , South Korea
Yeungnam University Hospital
Daegu, , South Korea
Hanyang University Guri Hospital
Guri-si, , South Korea
Inje University Ilsan Paik Hospital
Ilsan, , South Korea
National Health and Insurance Service Ilsan Hospital
Ilsan, , South Korea
Kosin Universithy Gospel Hospital
Pusan, , South Korea
Pusan National University Hospital
Pusan, , South Korea
Korea Cancer Center Hospital
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Choong Ang University Hospital
Seoul, , South Korea
Hallym University Hospital
Seoul, , South Korea
Hanyang University Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Soonchunhyang University Hospital
Seoul, , South Korea
Ajou University Hospital
Suwon, , South Korea
Ulsan University Hospital
Ulsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Young Rok Do
Role: primary
Dok Hyun Yoon, M.D.,Ph.D.
Role: primary
Won Seog Kim, M.D., Ph.D.
Role: primary
Seong Hyun Jeong, M.D.,Ph.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Giraffe-T
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.